IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.66B
5Y Perf.+8.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IMVT vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1669.52T
5Y Perf.-59.8%
IMVT vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IMVT | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5.66B | $1669.52T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-464M | $-168M |
| Total Debt | $98K | $22M |
| Cash & Equiv. | $714M | $194M |
IMVT vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMVT
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 100 | 108.5 | +8.5% |
| DBV Technologies S.… (DBVT) | 100 | 40.2 | -59.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMVT vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
IMVT
Immunovant, Inc.
The Growth Play
IMVT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth -45.2%
- 179.8% 10Y total return vs DBVT's -87.1%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs IMVT's 1.37
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs DBVT's -100.0% |
| Quality / Margins | IMVT | 3.2% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.7% vs IMVT's +82.9% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs DBVT's -89.0% |
IMVT vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IMVT and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$487M | -$112M |
| Net IncomeAfter-tax profit | -$464M | -$168M |
| Free Cash FlowCash after capex | -$423M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — IMVT and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $5.7B | $1669.52T |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $1669.52T |
| Trailing P/EPrice ÷ TTM EPS | -10.20x | -0.74x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 5.96x | 0.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IMVT and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-130 for DBVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -47.1% | -130.2% |
| ROA (TTM)Return on assets | -44.1% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -66.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.13x |
| Net DebtTotal debt minus cash | -$714M | -$172M |
| Cash & Equiv.Liquid assets | $714M | $194M |
| Total DebtShort + long-term debt | $98,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
IMVT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,976 today (with dividends reinvested), compared to $3,041 for DBVT. Over the past 12 months, DBVT leads with a +110.7% total return vs IMVT's +82.9%. The 3-year compound annual growth rate (CAGR) favors IMVT at 13.2% vs DBVT's 5.7% — a key indicator of consistent wealth creation.
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +7.4% | +2.3% |
| 1-Year ReturnPast 12 months | +82.9% | +110.7% |
| 3-Year ReturnCumulative with dividends | +45.0% | +18.1% |
| 5-Year ReturnCumulative with dividends | +69.8% | -69.6% |
| 10-Year ReturnCumulative with dividends | +179.8% | -87.1% |
| CAGR (3Y)Annualised 3-year return | +13.2% | +5.7% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.5% from its 52-week high vs DBVT's 74.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 1.26x |
| 52-Week HighHighest price in past year | $30.09 | $26.18 |
| 52-Week LowLowest price in past year | $13.36 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +92.5% | +74.4% |
| RSI (14)Momentum oscillator 0–100 | 55.8 | 43.7 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 249K |
Evenly matched — IMVT and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IMVT as "Buy" and DBVT as "Buy". Consensus price targets imply 137.7% upside for DBVT (target: $46) vs 63.4% for IMVT (target: $46).
| Metric | IMVTImmunovant, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.50 | $46.33 |
| # AnalystsCovering analysts | 23 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
IMVT vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMVT or DBVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMVT or DBVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +69. 8%, compared to -69. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IMVT returned +179. 8% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMVT or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 9% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — IMVT or DBVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -45. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMVT or DBVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — IMVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IMVT or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IMVT or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+179. 8% 10Y return). Both have compounded well over 10 years (IMVT: +179. 8%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMVT and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.